Wenjie Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Wenjie Wu has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Hua Deng
Department of Pediatric Internal Medicine, Chongqing Youyoubaobei Women and Children’s Hospital, Chongqing, China
2 shared publicationsQin Xie
Department of Pediatric Internal Medicine, Chongqing Youyoubaobei Women and Children’s Hospital, Chongqing, China
2 shared publications- Zhou Fu
Department of Respiratory Medicine Children’s Hospital of Chongqing Medical University, National Clinical Research Center for Children and Adolescents’ Health and Diseases, Ministry of Education Key Laboratory of Child Development and Disorders
2 shared publications - Chang Hao
Department of Respiratory Medicine, Children’s Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing Engineering Research Center of Stem Cell Therapy, Chongqing 400014, China
1 shared publication - Daiyin Tian
Ministry of Education Key Laboratory of Child Development and Disorders, Department of Respiratory Medicine, Children's Hospital of Chongqing Medical University National Clinical Research Center for Children and Adolescents' Health and Diseases Chongqing China
1 shared publication Dao-Zhu Si
Department of Pediatrics, Chongqing Youyoubaobei Women and Children’s Hospital, Chongqing, China
1 shared publication
Latest Publications
- Open Access
- 5 January 2025
- Published by Wiley in Pediatric Discovery
- Vol. 3 (3)
CXCL14 increase dendritic cell antigen presentation and promote asthma immune response
Asthma is a chronic airway inflammatory disease characterized by reversible airflow limitation and airway hyperresponsiveness, which requires long‐term drug treatment and management. It is very important to study the etiology and pathogenesis of asthma for clinical asthma prevention and treatment. In this study, to understand the correlation between C‐X‐C motif chemokine ligand 14 (CXCL14) in bone marrow dendritic cells (BMDCs) and antigen presentation of asthma dendritic cells (DCs), an in vitro model of BMDCs was constructed for RNA sequencing (RNA‐seq). The changes of CXCL14 in BMDCs after house dust mites (HDM) stimulation were evaluated. Finally, evaluated the inflammation of the lung tissue in mice, and the expression of costimulatory molecules on the DCs surface in the lung tissue was analyzed by flow cytometry. The results showed that CXCL14 was upregulated in BMDCs after HDM stimulation, and its function was related to signal molecule interaction and the immune system. The expression of CXCL14 was increased in the HDM‐induced allergic asthma model. Knockdown of CXCL14 reduced the expression of costimulatory molecules CD86, CD80, and major histocompatibility complex II on the surface of DCs in the lung tissue of mice, induced immune tolerance, and reduced lung inflammatory cell infiltration and inflammatory factor levels, providing new ideas and theoretical basis for the clinical treatment of bronchial asthma.
- 5 January 2025
- Published by Wiley in Pediatric Discovery
- Vol. 3 (3)
Open AccessCXCL14 increase dendritic cell antigen presentation and promote asthma immune response
Asthma is a chronic airway inflammatory disease characterized by reversible airflow limitation and airway hyperresponsiveness, which requires long‐term drug treatment and management. It is very important to study the etiology and pathogenesis of asthma for clinical asthma prevention and treatment. In this study, to understand the correlation between C‐X‐C motif chemokine ligand 14 (CXCL14) in bone marrow dendritic cells (BMDCs) and antigen presentation of asthma dendritic cells (DCs), an in vitro model of BMDCs was constructed for RNA sequencing (RNA‐seq). The changes of CXCL14 in BMDCs after house dust mites (HDM) stimulation were evaluated. Finally, evaluated the inflammation of the lung tissue in mice, and the expression of costimulatory molecules on the DCs surface in the lung tissue was analyzed by flow cytometry. The results showed that CXCL14 was upregulated in BMDCs after HDM stimulation, and its function was related to signal molecule interaction and the immune system. The expression of CXCL14 was increased in the HDM‐induced allergic asthma model. Knockdown of CXCL14 reduced the expression of costimulatory molecules CD86, CD80, and major histocompatibility complex II on the surface of DCs in the lung tissue of mice, induced immune tolerance, and reduced lung inflammatory cell infiltration and inflammatory factor levels, providing new ideas and theoretical basis for the clinical treatment of bronchial asthma.
- Open Access
- 23 February 2024
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 24 (1) , 1-9
Identification and treatment of persistent small airway dysfunction in paediatric patients with asthma: a retrospective cohort study
Background: Asthma is a common respiratory disease. In asthma, the small airways have more intensive inflammation and prominent airway remodelling, compared to the central airways. We aimed to investigate the predictive value of risk factors and the fractional concentration of exhaled nitric oxide (FeNO) for persistent small airway dysfunction (p-SAD), and compare the effects of different treatment modalities. Methods: This retrospective cohort study included 248 children with asthma (aged 4–11 years). Binary logistic regression was used to analyse the risk factors for p-SAD. Correlations among FEV1/FVC, small airway function parameters, and FeNO levels in patients with asthma were analysed using Spearman’s rank correlation. The receiver operating characteristic curve and the Delong test were used to analyse the predictive value of FeNO for p-SAD. Differences in the treatment effects of inhaled corticosteroids (ICS) and ICS with a long-acting beta-agonist (ICS/LABA) on p-SAD were analysed using Fisher’s exact test. Results: Asthmatic children with older age of receiving the regular treatment (OR 1.782, 95% CI 1.082–2.935), with younger age at the time of onset of suspected asthma symptoms (OR 0.602, 95% CI 0.365–0.993), with longer duration of using ICS or ICS/LABA (OR 1.642, 95% CI 1.170–2.305) and with worse asthma control (OR 3.893, 95% CI 1.699–8.922) had increased risk for p-SAD. Significant negative correlations of small airway function parameters with FeNO at a 200 mL/s flow rate (FeNO200), and the concentration of nitric oxide in the alveolar or acinar region (CaNO) were observed. The areas under the curve of FeNO200 (cut-off:10.5ppb), CaNO (cut-off:5.1ppb), and FeNO200 combined with CaNO were 0.743, 0.697, and 0.750, respectively, for asthma with p-SAD. After using ICS or ICS/LABA, switching to ICS/LABA was easier than continuing with ICS to improve small airway dysfunction (SAD) in the 8th month. Conclusions: Paediatric asthma with p-SAD is associated with older age at receiving regular treatment, younger age at the time of onset of suspected asthma symptoms, longer duration of using ICS or ICS/LABA, worse asthma control, and higher FeNO200 and CaNO levels, all of which can be combined with small airway function indicators to distinguish p-SAD from asthma. ICS/LABA improves SAD better than ICS alone.
- 23 February 2024
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 24 (1) , 1-9
Open AccessIdentification and treatment of persistent small airway dysfunction in paediatric patients with asthma: a retrospective cohort study
Background: Asthma is a common respiratory disease. In asthma, the small airways have more intensive inflammation and prominent airway remodelling, compared to the central airways. We aimed to investigate the predictive value of risk factors and the fractional concentration of exhaled nitric oxide (FeNO) for persistent small airway dysfunction (p-SAD), and compare the effects of different treatment modalities. Methods: This retrospective cohort study included 248 children with asthma (aged 4–11 years). Binary logistic regression was used to analyse the risk factors for p-SAD. Correlations among FEV1/FVC, small airway function parameters, and FeNO levels in patients with asthma were analysed using Spearman’s rank correlation. The receiver operating characteristic curve and the Delong test were used to analyse the predictive value of FeNO for p-SAD. Differences in the treatment effects of inhaled corticosteroids (ICS) and ICS with a long-acting beta-agonist (ICS/LABA) on p-SAD were analysed using Fisher’s exact test. Results: Asthmatic children with older age of receiving the regular treatment (OR 1.782, 95% CI 1.082–2.935), with younger age at the time of onset of suspected asthma symptoms (OR 0.602, 95% CI 0.365–0.993), with longer duration of using ICS or ICS/LABA (OR 1.642, 95% CI 1.170–2.305) and with worse asthma control (OR 3.893, 95% CI 1.699–8.922) had increased risk for p-SAD. Significant negative correlations of small airway function parameters with FeNO at a 200 mL/s flow rate (FeNO200), and the concentration of nitric oxide in the alveolar or acinar region (CaNO) were observed. The areas under the curve of FeNO200 (cut-off:10.5ppb), CaNO (cut-off:5.1ppb), and FeNO200 combined with CaNO were 0.743, 0.697, and 0.750, respectively, for asthma with p-SAD. After using ICS or ICS/LABA, switching to ICS/LABA was easier than continuing with ICS to improve small airway dysfunction (SAD) in the 8th month. Conclusions: Paediatric asthma with p-SAD is associated with older age at receiving regular treatment, younger age at the time of onset of suspected asthma symptoms, longer duration of using ICS or ICS/LABA, worse asthma control, and higher FeNO200 and CaNO levels, all of which can be combined with small airway function indicators to distinguish p-SAD from asthma. ICS/LABA improves SAD better than ICS alone.
- Open Access
- 7 September 2023
- Published by Wiley in Pediatric Discovery
- Vol. 1 (2)
Importance of early follow‐up of Mycoplasma pneumoniae pneumonia in pediatric patients: A case series
- 7 September 2023
- Published by Wiley in Pediatric Discovery
- Vol. 1 (2)
Open AccessImportance of early follow‐up of Mycoplasma pneumoniae pneumonia in pediatric patients: A case series
- Open Access
- 27 June 2022
- Published by Wiley in Stem Cells International
- Vol. 2022, 1-16
Microvesicles Derived from Human Umbilical Cord Mesenchymal Stem Cells Enhance Alveolar Type II Cell Proliferation and Attenuate Lung Inflammation in a Rat Model of Bronchopulmonary Dysplasia
Although it is known that exosomes derived from human umbilical cord mesenchymal stem cells (hUCMSCs) alleviate hyperoxic lung injury of bronchopulmonary dysplasia (BPD) in animal models, the role of microvesicles (MVs) derived from hUCMSCs in BPD is poorly defined. Furthermore, antenatal inflammation has been linked to high risk of BPD in preterm infants. The purpose of this study was to explore whether MVs derived from hUCMSCs can preserve lung structure and function in an antenatal lipopolysaccharide- (LPS-) induced BPD rat model and to clarify the underlying mechanism. We demonstrate that antenatal LPS induced alveolar simplification, altered lung function, and dysregulated pulmonary vasculature, which restored by hUCMSCs and MVs treatment. Furthermore, MVs were large vesicles with a diameter of 100-900 nanometers and mostly uptaken by alveolar epithelial type II cells (AT2) and macrophages. Compared with the LPS-exposed group, MVs restored the AT2 cell number and SP-C expression in vivo and promoted the proliferation of AT2 cells in vitro. MVs also restored the level of IL-6 and IL-10 in lung homogenate. Additionally, PTEN/AKT and MAPK pathways were associated with the protection of MVs. Taken together, this study suggests MVs derived from hUCMSCs improve lung architecture and function in an antenatal LPS-induced BPD rat model by promoting AT2 cell proliferation and attenuating lung inflammation; thus, MVs provide a promising therapeutic vehicle for BPD treatment.
- 27 June 2022
- Published by Wiley in Stem Cells International
- Vol. 2022, 1-16
Open AccessMicrovesicles Derived from Human Umbilical Cord Mesenchymal Stem Cells Enhance Alveolar Type II Cell Proliferation and Attenuate Lung Inflammation in a Rat Model of Bronchopulmonary Dysplasia
Although it is known that exosomes derived from human umbilical cord mesenchymal stem cells (hUCMSCs) alleviate hyperoxic lung injury of bronchopulmonary dysplasia (BPD) in animal models, the role of microvesicles (MVs) derived from hUCMSCs in BPD is poorly defined. Furthermore, antenatal inflammation has been linked to high risk of BPD in preterm infants. The purpose of this study was to explore whether MVs derived from hUCMSCs can preserve lung structure and function in an antenatal lipopolysaccharide- (LPS-) induced BPD rat model and to clarify the underlying mechanism. We demonstrate that antenatal LPS induced alveolar simplification, altered lung function, and dysregulated pulmonary vasculature, which restored by hUCMSCs and MVs treatment. Furthermore, MVs were large vesicles with a diameter of 100-900 nanometers and mostly uptaken by alveolar epithelial type II cells (AT2) and macrophages. Compared with the LPS-exposed group, MVs restored the AT2 cell number and SP-C expression in vivo and promoted the proliferation of AT2 cells in vitro. MVs also restored the level of IL-6 and IL-10 in lung homogenate. Additionally, PTEN/AKT and MAPK pathways were associated with the protection of MVs. Taken together, this study suggests MVs derived from hUCMSCs improve lung architecture and function in an antenatal LPS-induced BPD rat model by promoting AT2 cell proliferation and attenuating lung inflammation; thus, MVs provide a promising therapeutic vehicle for BPD treatment.
- Open Access
- 18 August 2021
- Published by Springer Nature in World Journal of Pediatrics
- Vol. 17 (5) , 557-559
Acute generalized exanthematous pustulosis as a manifestation of Kawasaki disease
- 18 August 2021
- Published by Springer Nature in World Journal of Pediatrics
- Vol. 17 (5) , 557-559
Open AccessAcute generalized exanthematous pustulosis as a manifestation of Kawasaki disease